Peptide Supplied: who produces the next hormone?

An overnight growth-hormone study

Thirteen healthy men received tesamorelin for two weeks. In the study of their overnight growth-hormone secretion, mean overnight GH increased by +0.5 ug/L and IGF-1 rose by 181 ug/L; neither fasting glucose nor insulin-stimulated glucose uptake changed significantly. Tesamorelin stimulated their pituitaries to release growth hormone. The men supplied that next hormone themselves.

That is a surprisingly busy meaning of “supplied.” I initially imagined an addition to the bloodstream; that experiment moved the activity back inside the body. Its measurements concern hormone secretion and glucose handling in healthy men over two weeks. A claim about lasting fat loss would require a different experiment.

Pituitary stimulation

Tesamorelin resembles growth hormone-releasing hormone, the signal that prompts the pituitary to secrete GH. The healthy-men experiment examined that endogenous rhythm—endogenous simply means made inside the body. The distinction matters because a stimulation experiment leaves the responding organ at work.

The clinical fat-loss evidence comes from adults with HIV-associated lipodystrophy. Tesamorelin’s FDA-approved indication is confined to excess abdominal fat in that population. I admire the pituitary’s contribution here; the leap from a working pituitary to an all-purpose body-composition treatment remains much too large. The tesamorelin page follows both the secretion study and the abdominal-fat trials.

Three different supply arrangements

Retatrutide’s engineered molecule engages GIP, GLP-1 and glucagon receptors. It combines activities associated with several natural hormones in one synthetic peptide. The retatrutide page asks what that combined signal achieved in weight, glucose and liver-fat trials, alongside the stomach trouble and faster pulse.

MOTS-c is encoded in mitochondrial DNA and occurs in muscle and circulation. The body has its own supply, and exercise can raise it. Experiments giving extra MOTS-c to mice ask a further question. The MOTS-c page separates those additions from observations of the peptide already present in people.

For a compact comparison, follow the supplied signal across the three compounds. Their names share a conversation; their biological jobs differ considerably.

Peptide deficiency claims

“Supply” invites a story about a shortage being filled. None of the findings above, on its own, diagnoses a peptide shortage in the person reading it. The studies tested particular interventions or measured particular signals. That leaves a demanding question: which change in the body actually explains the outcome?

I’d give that question more space than another catalogue of possible benefits. The FAQ deals with the names metatrutide and metatrolide, the three peptides together, and the practical questions that often arrive before the biology.